


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-2 (canceled).

3 (previously presented). 2-((2-Bromoethyl)-2-[(2-hydroxyethyl)amino]carbonyl)-4,6-dinitroanilino)ethyl methanesulfonate.

4 (previously presented). A nitroaniline-based unsymmetrical mustard represented by formula (IIIb)



wherein


X represents one of the groups  $\text{NO}_2$ ,  $\text{CN}$ , or  $\text{SO}_2\text{R}^1$ , where  $\text{R}^1$  represents a  $\text{C}_{1-6}$ -alkyl optionally substituted with one or more hydroxy and/or one or more amino groups;

Y represents one of the groups  $\text{OR}^2$ ,  $\text{NHCOR}^2$ ,  $\text{CONHR}^2\text{CO}_2\text{R}^3$ ,

CONHR<sup>2</sup>morpholide, CONHR<sup>2</sup> other than CONH<sub>2</sub>, CONR<sup>2</sup>R<sup>3</sup> other than CONH<sub>2</sub>, CONHOR<sup>2</sup>, CONHSO<sub>2</sub>R<sup>2</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>2</sup> or SO<sub>2</sub>NR<sup>2</sup>R<sup>3</sup> wherein each R<sup>2</sup> and R<sup>3</sup> independently represent a H, C<sub>1-6</sub>- alkyl or C<sub>1-6</sub>-alkylene optionally substituted with one or more hydroxy and/or one or more amino groups; and A and B each independently represent halogen, OSO<sub>2</sub>R<sup>4</sup>, OSO<sub>2</sub>NH<sub>2</sub>, OSO<sub>2</sub>NHR<sup>4</sup> or OSO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, wherein each R<sup>4</sup> and R<sup>5</sup> independently represent a C<sub>1-6</sub>- alkyl optionally substituted with one or more hydroxy and/or one or more amino groups; and pharmaceutically acceptable derivatives and salts thereof.

5-7 (canceled).

8 (previously presented). A method of preparing a nitroaniline-based unsymmetrical mustard represented by formula (IIIb) as claimed in claim 4




wherein

X represents one of the groups NO<sub>2</sub>, CN, or SO<sub>2</sub>R<sup>1</sup>, where R<sup>1</sup> represents a C<sub>1-6</sub>-

alkyl optionally substituted with one or more hydroxy and/or one or more amino groups;

Y represents one of the groups  $OR^2$ ,  $NHCO R^2$ ,  $CONHR^2CO_2R^3$ ,  $CONHR^2$ morpholide,  $CONHR^2$  other than  $CONH_2$ ,  $CONR^2R^3$  other than  $CONH_2$ ,  $CONHOR^2$ ,  $CONHSO_2R^2$ ,  $SO_2NH_2$ ,  $SO_2NHR^2$  or  $SO_2NR^2R^3$  wherein each  $R^2$  and  $R^3$  independently represent a H,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkylene optionally substituted with one or more hydroxy and/or one or more amino groups; and A and B each independently represent halogen,  $OSO_2R^4$ ,  $OSO_2NH_2$ ,  $OSO_2NHR^4$  or  $OSO_2NR^4R^5$ , wherein each  $R^4$  and  $R^5$  independently represent a  $C_{1-6}$ -alkyl optionally substituted with one or more hydroxy and/or one or more amino groups; and pharmaceutically acceptable derivatives and salts thereof;

the method comprising the step of reacting a compound of formula



with an amount of  $LiBr$  in a polar solvent to give a bromo mesylate of formula (IIIb).

9 (previously presented). The method as claimed in claim 8 wherein the polar solvent is selected from the group consisting of acetonitrile, dimethylformamide, ethyl acetate, triethylamine, acetone and mixtures thereof.

10 (previously presented). The method as claimed in claim 8 wherein the alkali metal halide is selected from the group consisting of LiCl, LiBr, NaI and NaBr.

11 (previously presented). A compound of formula (IIIb) obtained by any one of the methods as claimed in claim 8.

12-15 (canceled).

16 (currently amended). A method of cell ablation therapy utilising at least one endogenous nitroreductase enzyme, the method comprising the step of administering a compound of Formula (IIIb) as claimed in claim 4 in a "therapeutically effective amount" to ablate tumour cells in tissue in a subject, wherein said ~~tissue expresses~~ tumor cells have regions of hypoxia and express at least one endogenous nitroreductase enzyme, to activate the compound of formula (IIIb) into an active metabolite to ablate the tumor cells.

17-18 (canceled).

19 (previously presented). A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (IIIb) as defined in claim 4 and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.

20-21(canceled).

22 (previously presented). A nitroaniline-based unsymmetrical mustard as claimed in claim 4, wherein Y is  $\text{CONHR}_2$  where  $\text{R}_2$  is  $\text{C}_1\text{-C}_6$  alkylene substituted with hydroxyl.

23(previously presented). A nitroaniline-based unsymmetrical mustard as claimed in claim 4, wherein Y is  $\text{CONHCH}_2\text{CH}_2\text{OH}$ .